RECRUITING

Mood and Decision-making in Methamphetamine Use Disorder

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this project, the investigators examine behavior and associated brain activity during explore-exploit decision-making tasks performed pre- and post-modulation of affective state using autobiographical memory recall. The investigators hypothesize that a positive memory recall will reduce negative affective state, reduce explore-exploit biases and normalize the associated brain activity. The investigators propose a randomized double-blind, sham-controlled trial of positive autobiographical memory recall with 80 adults (n=40 per arm) with methamphetamine use disorder (MUD) currently involved in abstinence only treatment centers.

Official Title

Modulating Explore-exploit Biases by Improving Mood in Adults With Methamphetamine Use Disorder

Quick Facts

Study Start:2024-07-26
Study Completion:2026-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06410196

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults 18-65 years old
  2. * English proficiency as evaluated by language ability during screening
  3. * Past-year diagnosis of DSM-5 methamphetamine use disorder (MUD) confirmed by the MINI
  4. * Actively enrolled in treatment for substance use disorder.
  1. * Severe traumatic brain injury (as indicated by a score ≥3 on the Tulsa Head Injury Screen
  2. * Any medical condition interfering with the participation in the study as determined by medical screening
  3. * DSM-5 diagnosis of psychotic disorders, bipolar I disorder, or major depressive disorder with psychosis
  4. * fMRI contraindications as listed on the MR environment screening form
  5. * Positive breathalyzer for alcohol
  6. * Positive urine drug screening, except for cannabis or prescribed benzodiazepines, as indicated in the medical screening
  7. * Evidence of inability to comply with study procedures based on judgement of the experimenter.

Contacts and Locations

Study Contact

Maëlle CM Gueguen, PhD
CONTACT
918-502-5155
mgueguen@laureateinstitute.org

Principal Investigator

Maelle Gueguen, PhD
PRINCIPAL_INVESTIGATOR
Laureate Institute for Brain Research, Inc.

Study Locations (Sites)

Laureate Institute for Brain Research
Tulsa, Oklahoma, 74136
United States

Collaborators and Investigators

Sponsor: Laureate Institute for Brain Research, Inc.

  • Maelle Gueguen, PhD, PRINCIPAL_INVESTIGATOR, Laureate Institute for Brain Research, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-26
Study Completion Date2026-07

Study Record Updates

Study Start Date2024-07-26
Study Completion Date2026-07

Terms related to this study

Additional Relevant MeSH Terms

  • Methamphetamine Abuse